Table 2. Pretreatment patient characteristics.
All patients (N = 45)
Male, n (%)23 (51)
Age (years), median (range)64 (38–90)
Cancer type, n (%)
  Melanoma21 (47)
  Ovarian6 (13)
  Sarcoma*5 (11)
  Non–small cell lung cancer4 (9)
  Colorectal4 (9)
  Other5 (11)
Distant metastases, n (%)39 (87)
Previous anticancer treatment
regimens, median (range)
3 (0–10)
NY-ESO-1+ tumor, n (%)27 (64)

*Sarcoma subtypes were leiomyosarcoma (n = 2), endometrial stromal sarcoma, adipocytic, and round cell liposarcoma.

†Other tumor types included cholangiocarcinoma; carcinoid tumor of liver, anal, and bladder; and myeloma.

‡Tumor NY-ESO-1 expression status is unknown for three patients.